Search results for "Immune system"

showing 10 items of 2885 documents

Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies?

2015

The first objective to use chemotherapy is to kill cancer cells. However, it is common knowledge that these drugs can also damage healthy host cells, especially immune cells, and thus impair the endogenous antitumor response. Here, we focus on the cytotoxic effects of chemotherapy on tumor cells and immune cells. It is not enough to simply kill cancer cells, and causing immunogenic cell death will impair the adaptive immune system's ability to fight the remaining cancer cells. On the other hand, the killing of immune cells can also enhance tumor growth. A study of the repercussions of the cytotoxic effects of chemotherapy is of great importance to evaluate the antitumor response. Strategie…

Cancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentCancerchemical and pharmacologic phenomenaGeneral MedicineSuicide genemedicine.diseaseAcquired immune systemImmune systemOncologyImmunologyCancer cellMedicineImmunogenic cell deathCytotoxic T cellbusinessFuture Oncology
researchProduct

OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.

2015

e16576 Background: Treatment of ovarian cancer (OC) remains very challenging, with 80-85% of the cases still dying after relapse to standard chemotherapy, and novel treatments are urgently needed. Expansion of regulatory T cells (Tregs) is considered the major factor limiting immune responses to OC. Agonist antibodies against the co-stimulatory receptor OX40 have recently demonstrated to abrogate Treg functions and are under clinical evaluation. We thus studied whether OX40 constituted a valid target of OC-associated Tregs. Methods: Treg immunophenotypic analyses were performed by flow cytometry in ascites and OC specimens and studied in association with patients’ outcome Results: CD4+CD25+…

Cancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentFOXP3hemic and immune systemschemical and pharmacologic phenomenaOvarymedicine.diseaseSerous fluidmedicine.anatomical_structureImmune systemOncologyAscitesmedicineCancer researchIL-2 receptormedicine.symptomOvarian cancerbusinessJournal of Clinical Oncology
researchProduct

Risk of coronavirus disease 2019 in patients treated for cancer: An immune response–based hypothesis

2020

Cancer ResearchCoronavirus disease 2019 (COVID-19)Pneumonia Viralhumans; betacoronavirus; coronavirus; coronavirus infections; pandemics; pneumonia; viralcoronaviruspandemicsmedicine.disease_causeArticlecoronavirus infectionsImmune systemPandemicmedicinepneumoniaIn patienthumansCoronavirusbiologySARS-CoV-2business.industryCOVID-19Cancerbiology.organism_classificationmedicine.diseasebetacoronavirusPneumoniaOncologyImmunologybusinessBetacoronavirusviralEuropean Journal of Cancer
researchProduct

T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Mod…

2021

AbstractTumors undergo dynamic immunoediting as part of a process that balances immunologic sensing of emerging neoantigens and evasion from immune responses. Tumor-infiltrating lymphocytes (TIL) comprise heterogeneous subsets of peripheral T cells characterized by diverse functional differentiation states and dependence on T-cell receptor (TCR) specificity gained through recombination events during their development. We hypothesized that within the tumor microenvironment (TME), an antigenic milieu and immunologic interface, tumor-infiltrating peripheral T cells could reexpress key elements of the TCR recombination machinery, namely, Rag1 and Rag2 recombinases and Tdt polymerase, as a poten…

Cancer ResearchDatasets as TopicT-Cell Antigen Receptor SpecificityCD8-Positive T-LymphocytesMice0302 clinical medicineTumor MicroenvironmentRecombinaseT-cell receptorBreastRNA-SeqT Cells T Cell Receptor Recombination/Revision Machinery Tumor MicroenvironmentCancerAged 80 and overMice KnockoutRecombination GeneticNuclear Proteinshemic and immune systemsMiddle AgedDNA-Binding Proteins030220 oncology & carcinogenesisFemaleSingle-Cell AnalysisMutL Protein Homolog 1AdultImmunologyReceptors Antigen T-CellT cellsBreast Neoplasmschemical and pharmacologic phenomenaSettore MED/08 - Anatomia PatologicaBiologyRecombination-activating gene03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemAntigenDNA NucleotidylexotransferaseRAG2AnimalsHumansSettore MED/05 - Patologia ClinicaAgedHomeodomain ProteinsTumor microenvironmentT-cell receptorDisease Models AnimalImmunoeditingCancer researchDNA Damage030215 immunology
researchProduct

Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells

2004

The ability of tumour cells to resist apoptosis-inducing signals by cytotoxic T cells may decide the success or failure of tumour elimination. An important effector of apoptosis is the CD95/CD95 ligand system (APO-1/Fas) that mediates perforin-independent cytotoxic T-cell killing of tumour cells. We propose a new strategy by which tumour cells can resist CD95-induced apoptosis. We identified matrix metalloproteinase-7, MMP-7 (Martilysin), as the first physiologically relevant protease that can specifically cleave CD95. MMP-7 is of unique importance because it is produced by the tumour cells themselves at early stages of tumour development. Microsequencing of the positions in CD95 cleaved by…

Cancer ResearchEffectorApoptosishemic and immune systemschemical and pharmacologic phenomenaBiologyMatrix metalloproteinaseFas receptorCleavage (embryo)medicine.disease_causeCell biologyApoptosisMatrix Metalloproteinase 7hemic and lymphatic diseasesTumor Cells CulturedGeneticsExtracellularmedicineHumansCytotoxic T cellfas Receptorbiological phenomena cell phenomena and immunityCarcinogenesisMolecular BiologyOncogene
researchProduct

Abstract 3100: Replacing fetal calf serum by human platelet lysate in cancer research and toxicology

2018

Abstract Experiments with cultured mammalian cells represent a common in vitro alternative to animal experiments. Fetal calf serum (FCS) is the most commonly used medium supplement. FCS contains a mixture of largely undefined growth factors and cytokines. Since FCS is received from unborn calves older than three months, it represents a massive burden for the pregnant cows and their fetuses. A needle is inserted into the heart of the fetus to collect blood. Since the animal is not under anesthesia, it may suffer pain and discomfort. Furthermore, the undefined nature of FCS is a source of experimental variation, undesired immune responses, and possible contaminations. Thus, alternative, defin…

Cancer ResearchFetusmedicine.diagnostic_testCell growthCancerCell cycleBiologyCell morphologymedicine.diseaseFlow cytometryToxicologyImmune systemOncologyCell cultureCancer researchmedicineCancer Research
researchProduct

Induction of immunogenicity of a human renal-cell carcinoma cell line byTAP1-gene transfer

1999

Reduced expression of the major-histocompatibility-complex(MHC)-class-I antigens has been demonstrated in renal-cell carcinoma (RCC), and appeared to be associated with deficiencies in the expression and function of different components of the MHC-class-I-antigen-processing pathway and poor recognition by cytotoxic T-lymphocytes (CTL). In order to investigate the role of peptide transporters for the immunogenic phenotype of RCC, tumor cells were stably transfected with the human TAP1A gene. While the TAP1 transfectants showed heterogeneous TAP1-transgene expression pattern of mRNA and protein, high TAP1 expression and a TAP-controlled increase in MHC-class-I surface expression could be achi…

Cancer ResearchGenetic transferTransfectionBiologyurologic and male genital diseasesMajor histocompatibility complexImmune toleranceImmune systemOncologyAntigenCell cultureImmunologyCancer researchbiology.proteinCytotoxic T cellInternational Journal of Cancer
researchProduct

Presence of the Transmembrane Protein Neuropilin in Cytokine-induced Killer Cells

2020

Background/aim Cytokine-induced killer (CIK) cells are a heterogenous population of immune cells showing promising applications in immunotherapeutic cancer treatment. Neuropilin (NRP) proteins have been proven to play an important role in cancer development and prognosis. In this study, CIK cells were tested for expression of NRPs, transmembrane proteins playing a role in the proliferation and survival of cancer cells. Materials and methods CIK cells were analyzed at different time points via flow cytometry and quantitative real-time polymerase chain reaction for neuropilin expression. Results Phenotyping results showed CIK cells having developed properly, and low levels of NRP2 were detect…

Cancer ResearchImmunologyCellBiologyFlow cytometryCytokine-Induced Killer CellsImmune systemNeoplasmsNeuropilin 1medicineNeuropilinHumansNeuropilinsFlow cytometryNeuropilin.A549 cellmedicine.diagnostic_testCytokine-induced killer cellGeneral MedicinePrognosisNeuropilin-1Neuropilin-2Gene Expression Regulation NeoplasticBrain tumorCytokine-induced killer cellmedicine.anatomical_structureOncologyA549 CellsCancer cellCancer researchImmunotherapyLung cancerAnticancer Research
researchProduct

Abstract 1631: GPR65 is a critical mediator of low pH induced immunosuppressive signalling in tumor associated macrophages: Human target validation o…

2021

Abstract Tumor-associated macrophages (TAMs) are the major innate immune component in the microenvironment of solid tumors. These cells are highly heterogeneous and plastic but often display a pronounced immunosuppressive phenotype that supports primary tumor growth and metastasis. A recently identified determinant of the immunosuppressive properties of TAMs is the activation of the pH-sensing G protein-coupled receptor, GPR65, on these cells by the acidic microenvironment that is inherent to many advanced solid tumours1. Previous work in mouse macrophages has shown that GPR65 activation leads to an elevation of inducible cAMP early repressor (ICER), an isoform of the CREM gene, which in tu…

Cancer ResearchInnate immune systemmedicine.medical_treatmentT cellCancerImmunosuppressionImmunotherapyBiologymedicine.diseasePrimary tumorProinflammatory cytokinemedicine.anatomical_structureOncologymedicineCancer researchMacrophageCancer Research
researchProduct

Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms

2016

Abstract Mechanisms of antiviral host defense are important for survival and evolutionarily optimized for high sensitivity and potency. Intending to harvest the multitude of highly specialized and intertwined pathogen immune defense programs for cancer immunotherapy, we simulated a systemic pathogen intrusion into the blood stream by intravenous injection of lipid-formulated, tumor antigen-encoding mRNA nanoparticles. These RNA-lipoplexes (RNA-LPX) were directed to various lymphoid tissues, including the spleen, lymph nodes and bone marrow, which provide the ideal microenvironment for efficient priming and amplification of T cell responses. Solely the RNA-to-lipid ratio was discovered to de…

Cancer ResearchInnate immune systemmedicine.medical_treatmentT cellImmunologyTLR7Biologymedicine.anatomical_structureCancer immunotherapyAntigenImmunologymedicineCytotoxic T cellAntigen-presenting cellCD8Cancer Immunology Research
researchProduct